Affordable Access

deepdyve-link
Publisher Website

Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.

Authors
  • Basourakos, Spyridon P1
  • Davis, John W2
  • Chapin, Brian F2
  • Ward, John F2
  • Pettaway, Curtis A2
  • Pisters, Louis L2
  • Navai, Neema2
  • Achim, Mary F2
  • Wang, Xuemei3
  • Chen, Hsiang-Chun3
  • Choi, Seungtaek4
  • Kuban, Deborah4
  • Troncoso, Patricia5
  • Hanash, Sam6
  • Thompson, Timothy C1
  • Kim, Jeri1
  • 1 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • 2 Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • 3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • 4 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • 5 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • 6 Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Type
Published Article
Journal
British Journal of Urology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Jan 01, 2018
Volume
121
Issue
1
Pages
69–76
Identifiers
DOI: 10.1111/bju.13963
PMID: 28710901
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To evaluate the role of caveolin-1 (Cav-1) as a predictor of disease reclassification (DR) in men with early prostate cancer undergoing active surveillance (AS). We analysed archived plasma samples prospectively collected from patients with early prostate cancer in a single-institution AS study. Of 825 patients enrolled, 542 had ≥1 year of follow-up. Baseline and longitudinal plasma Cav-1 levels were measured using an enzyme-linked immunosorbent assay. Tumour volume or Gleason grade increases were criteria for DR. Logistic regression analyses were used to assess associations between clinicopathological characteristics and reclassification risk. In 542 patients, 480 (88.6%) had stage cT1c disease, 542 (100.0%) had a median prostate-specific antigen level of 4.1 ng/mL, and 531 (98.0%) had a median Cancer of the Prostate Risk Assessment score of 1. In all, 473 (87.3%) had a Gleason score of 3+3. After a median of 3.1 years of follow-up, disease was reclassified in 163 patients (30.1%). The mean baseline Cav-1 level was 2.2 ± 8.5 ng/mL and the median 0.2 ng/mL (range, 0-85.5 ng/mL). In univariate analysis, baseline Cav-1 was a significant predictor for risk of DR (odds ratio [OR] 1.82, 95% confidence interval [CI] 1.24-2.65; P = 0.002). In multivariate analysis, with adjustments for age, tumour length, group risk stratification and number of positive cores, reclassification risk associated with Cav-1 remained significant (OR 1.91, 95% CI 1.28-2.84; P = 0.001). Baseline plasma Cav-1 level was an independent predictor of disease classification. New methods for refining AS and intervention may result. © 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd.

Report this publication

Statistics

Seen <100 times